These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 25696879)
21. Strategies for Individualized Dosing of Clotting Factor Concentrates and Desmopressin in Hemophilia A and B. Preijers T; Schütte LM; Kruip MJHA; Cnossen MH; Leebeek FWG; van Hest RM; Mathôt RAA Ther Drug Monit; 2019 Apr; 41(2):192-212. PubMed ID: 30883513 [TBL] [Abstract][Full Text] [Related]
26. Biological rationale for new drugs in the bleeding disorders pipeline. Fogarty PF Hematology Am Soc Hematol Educ Program; 2011; 2011():397-404. PubMed ID: 22160064 [TBL] [Abstract][Full Text] [Related]
27. Trends in the utilization and wastage of coagulation factor concentrates: the application of a regional tracking programme. Arnold DM; Webert KE; Carruthers J; Almonte T; Decker K; Seroski W; Reed J; Chan AK; Pai M; Walker I Haemophilia; 2007 May; 13(3):271-8. PubMed ID: 17498076 [TBL] [Abstract][Full Text] [Related]
28. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia. Mahdi AJ; Obaji SG; Collins PW Br J Haematol; 2015 Jun; 169(6):768-76. PubMed ID: 25754016 [TBL] [Abstract][Full Text] [Related]
31. Ex Vivo Stromal Cell Electroporation of Factor IX cDNA for Treatment of Hemophilia B. Keating A; Nolan E; Filshie R; Dev SB Methods Mol Med; 2000; 37():359-68. PubMed ID: 21445754 [TBL] [Abstract][Full Text] [Related]
32. Treatment strategies in children with hemophilia. Petrini P Paediatr Drugs; 2002; 4(7):427-37. PubMed ID: 12083971 [TBL] [Abstract][Full Text] [Related]
33. The improved factor concentrate. Lillicrap D Hamostaseologie; 2009 Jan; 29(1):71-3. PubMed ID: 19151851 [TBL] [Abstract][Full Text] [Related]
34. Efficacy assessment of a new clotting factor concentrate in haemophilia A patients, including prophylactic treatment. Den Uijl I; Mauser-Bunschoten EP; Roosendaal G; Schutgens R; Fischer K Haemophilia; 2009 Nov; 15(6):1215-8. PubMed ID: 19686467 [TBL] [Abstract][Full Text] [Related]
35. Changing Paradigm of Hemophilia Management: Extended Half-Life Factor Concentrates and Gene Therapy. Kumar R; Dunn A; Carcao M Semin Thromb Hemost; 2016 Feb; 42(1):18-29. PubMed ID: 26771678 [TBL] [Abstract][Full Text] [Related]
36. Treatment of hemophilia. Rodeghiero F Ric Clin Lab; 1985; 15(4):289-303. PubMed ID: 3914697 [TBL] [Abstract][Full Text] [Related]
37. Acquired hemophilia in the patient suffering from rheumatoid arthritis: case report. Drobiecki A; Pasiarski M; Hus I; Sokołowska B; Wątek M Blood Coagul Fibrinolysis; 2013 Dec; 24(8):874-80. PubMed ID: 24042266 [TBL] [Abstract][Full Text] [Related]
38. Alternative strategies for gene therapy of hemophilia. Montgomery RR; Shi Q Hematology Am Soc Hematol Educ Program; 2010; 2010():197-202. PubMed ID: 21239794 [TBL] [Abstract][Full Text] [Related]
39. Hemophilia A in the third millennium. Franchini M; Mannucci PM Blood Rev; 2013 Jul; 27(4):179-84. PubMed ID: 23815950 [TBL] [Abstract][Full Text] [Related]
40. Bringing new therapy options to the hemophilia community. Bensen-Kennedy D Thromb Res; 2013 Mar; 131 Suppl 2():S15-8. PubMed ID: 23537722 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]